These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21172869)

  • 41. Rational considerations about development of live attenuated Yersinia pestis vaccines.
    Sun W; Curtiss R
    Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.
    Oyston PC; Mellado-Sanchez G; Pasetti MF; Nataro JP; Titball RW; Atkins HS
    Microb Pathog; 2010 May; 48(5):191-5. PubMed ID: 20096773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A live attenuated strain of Yersinia pestis ΔyscB provides protection against bubonic and pneumonic plagues in mouse model.
    Zhang X; Qi Z; Du Z; Bi Y; Zhang Q; Tan Y; Yang H; Xin Y; Yang R; Wang X
    Vaccine; 2013 May; 31(22):2539-42. PubMed ID: 23588087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.
    Li B; Zhou L; Guo J; Wang X; Ni B; Ke Y; Zhu Z; Guo Z; Yang R
    Infect Immun; 2009 Oct; 77(10):4356-61. PubMed ID: 19651863
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
    Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
    Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.
    Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA
    Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice.
    Wang S; Joshi S; Mboudjeka I; Liu F; Ling T; Goguen JD; Lu S
    Vaccine; 2008 Mar; 26(13):1664-74. PubMed ID: 18291562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current challenges in the development of vaccines for pneumonic plague.
    Smiley ST
    Expert Rev Vaccines; 2008 Mar; 7(2):209-21. PubMed ID: 18324890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Live-attenuated Yersinia pestis vaccines.
    Wang X; Zhang X; Zhou D; Yang R
    Expert Rev Vaccines; 2013 Jun; 12(6):677-86. PubMed ID: 23750796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Newly described cell type may prove valuable in development of plague vaccines against biowarfare.
    Expert Rev Vaccines; 2011 Mar; 10(3):259. PubMed ID: 21434794
    [No Abstract]   [Full Text] [Related]  

  • 51. Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection.
    Verma SK; Gupta A; Batra L; Tuteja U
    Vaccine; 2019 Jan; 37(1):19-24. PubMed ID: 30497835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Humoral and cellular immune response of mice challenged with Yersinia pestis antigenic preparations.
    Leal EA; Moreira JD; Nunes FF; Souza LR; Martins JM; Toledo VPC; Almeida AMP; Guimarães TMP
    Braz J Infect Dis; 2017; 21(6):620-626. PubMed ID: 29031042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection.
    Singh AK; Wang X; Sun W
    Vaccine; 2020 May; 38(21):3720-3728. PubMed ID: 32278523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.
    Bhattacharya D; Mecsas J; Hu LT
    Vaccine; 2010 Nov; 28(48):7683-9. PubMed ID: 20875494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of New Virulence Factors and Vaccine Candidates for
    Andersson JA; Sha J; Erova TE; Fitts EC; Ponnusamy D; Kozlova EV; Kirtley ML; Chopra AK
    Front Cell Infect Microbiol; 2017; 7():448. PubMed ID: 29090192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
    Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
    Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of memory B cell and plasma cell responses in the mice immunized with plague vaccines.
    Zhang X; Wang Q; Bi Y; Kou Z; Zhou J; Cui Y; Yan Y; Zhou L; Tan Y; Yang H; Du Z; Han Y; Song Y; Zhang P; Zhou D; Yang R; Wang X
    Scand J Immunol; 2014 Mar; 79(3):157-62. PubMed ID: 24383627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of bubonic and pneumonic plague using plant-derived vaccines.
    Alvarez ML; Cardineau GA
    Biotechnol Adv; 2010; 28(1):184-96. PubMed ID: 19931370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection.
    Szaba FM; Kummer LW; Duso DK; Koroleva EP; Tumanov AV; Cooper AM; Bliska JB; Smiley ST; Lin JS
    PLoS Pathog; 2014 May; 10(5):e1004142. PubMed ID: 24854422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.